Patients with clinically isolated syndromes (CIS) are prone to develop multiple sclerosis (MS). The randomized, placebo-controlled CHAMPS trial found early treatment with interferon -1a to be ...

A clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the antiviral remdesivir was not superior to treatment with remdesivir alone in hospitalized adults with ...

A clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the antiviral remdesivir was not superior to treatment with remdesivir alone in hospitalized adults with ...

Amid the coronavirus disease (COVID-19) pandemic, scientists and health experts race to develop drugs and vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Many ...

BUFFALO, N.Y. -- Specialists in neuroimaging at the University at Buffalo have proposed a mechanism by which interferon beta-1a may limit brain atrophy in multiple sclerosis (MS) patients. The ...

MS typically appears in young adulthood, but 3% to 5% of cases have an onset in early childhood or adolescence. No disease-modifying therapies have FDA approval for persons younger than 18 years of ...

The FDA has approved updated labeling for Rebif® (has approved updated labeling for Rebif® (interferon beta-1a; EMD Serono) to include the addition of new safety data on pregnancy and ...

A study published in this week’s issue of THE LANCET suggests that high-dose interferon beta-1b administered every other day is more effective than interferon beta-1a once a week for people with ...

Please provide your email address to receive an email when new articles are posted on . Researchers compared data from those treated in the phase 3 EVOLVE-MS-1 and DECIDE studies. Treatment with ...

A clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the antiviral remdesivir was not superior to treatment with remdesivir alone in hospitalized adults with ...